SUPN
SUPERNUS PHARMACEUTICALS, INC.
Key Financials
Revenue
$719.0M
↑ 8.6%
Operating Income
$-62283000
↓ 176.3%
EPS (Diluted)
$-0.68
↓ 151.5%
Net Income
$-38550000
↓ 152.2%
Total Liabilities
$390.9M
↑ 17.6%
Cash & Equivalents
$128.4M
↑ 85.3%
Total Assets
$1.5B
↑ 6.2%
Shareholders' Equity
$1.1B
↑ 2.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/6/2026 | View on SEC |
| 425 | 8/4/2026 | View on SEC |
| 425 | 8/3/2026 | View on SEC |
| DEFA14A | 8/3/2026 | View on SEC |
| 425 | 8/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SUPN |
| Company Name | SUPERNUS PHARMACEUTICALS, INC. |
| CIK | 1356576 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 301-838-2500 |